Takeda Pharmaceutical Company Limited
TAK
$15.91
$0.261.66%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -853.81M | 775.80M | 259.30M | 958.61M | 709.46M |
| Total Depreciation and Amortization | 4.42B | 4.86B | 4.72B | 4.76B | 4.74B |
| Total Amortization of Deferred Charges | 357.23M | 139.06M | 263.29M | 263.29M | 263.29M |
| Total Other Non-Cash Items | 1.79B | 2.49B | 2.27B | 1.48B | 1.64B |
| Change in Net Operating Assets | 1.23B | -320.93M | 516.29M | -108.88M | -390.04M |
| Cash from Operations | 6.94B | 7.94B | 8.03B | 7.36B | 6.96B |
| Capital Expenditure | -1.16B | -1.19B | -1.22B | -1.28B | -1.32B |
| Sale of Property, Plant, and Equipment | 44.64M | 44.52M | 44.47M | 44.67M | 515.30K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 228.96M | 297.70M | 285.42M | 319.28M | 135.34M |
| Other Investing Activities | -1.52B | -1.32B | -553.52M | -705.69M | -1.22B |
| Cash from Investing | -2.41B | -2.18B | -1.44B | -1.62B | -2.40B |
| Total Debt Issued | 586.06B | 553.55B | 593.55B | 727.87B | 1.05T |
| Total Debt Repaid | -584.98B | -730.36B | -1.23T | -1.47T | -1.37T |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -51.60B | -101.58B | -101.58B | -101.58B | -51.86B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.09B | -2.10B | -2.08B | -2.09B | -1.97B |
| Other Financing Activities | -134.39B | -129.88B | -135.99B | -127.54B | -82.75B |
| Cash from Financing | -3.30B | -4.80B | -7.85B | -8.51B | -4.99B |
| Foreign Exchange rate Adjustments | 226.27M | 155.74M | 160.13M | -211.61M | -84.27M |
| Miscellaneous Cash Flow Adjustments | -6.30K | 6.60K | 6.60K | 6.60K | 6.60K |
| Net Change in Cash | 1.46B | 1.12B | -1.10B | -2.99B | -517.05M |